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Abstract 
Hyaluronic acid, a natural CD44 receptor ligand, has attracted attention in the past years as a 
macromolecular delivery of anticancer agents to cancer. At the same time, the clinical applications of 
Gemcitabine (Gem) have been hindered by its short biological half-life, high dose and development of 
drug resistance. This work reports the synthesis of a hyaluronic acid (HA) conjugate for nuclear imaging, 
and in vivo Gem delivery to CD44-expressing solid tumors in mice. HA was individually conjugated, via 
amide coupling, to Gem (HA-Gem), 4'-(aminomethyl)fluorescein hydrochloride (HA-4’-AMF) or 
tris(hydroxypyridinone) amine (HA-THP) for cancer therapy, in vitro tracking or single photon emission 
computed tomography/computed tomography (SPECT/CT) imaging, respectively. Gem conjugation to 
HA was directly confirmed by nuclear magnetic resonance (1H NMR), gel permeation chromatography 
(GPC) and UV–visible spectrometry, or indirectly by a nucleoside transporter inhibition study. Gem 
conjugation to HA improved its plasma stability, reduced blood hemolysis and resulted in delayed 
cytotoxicity in vitro. Uptake inhibition studies in colon CT26 and pancreatic PANC-1 cells, by flow 
cytometry, revealed that uptake of fluorescent HA conjugate is CD44 receptor and 
macropinocytosis-dependent. Gamma scintigraphy and SPECT/CT imaging confirmed the relatively 
prolonged blood circulation proﬁle and uptake in CT26 (1.5 % ID/gm) and PANC-1 (1 % ID/gm) 
subcutaneous tumors at 24 h after intravenous injection in mice. Four injections of HA-Gem at ~15 
mg/kg, over a 28-day period, resulted in significant delay in CT26 tumor growth and prolonged mice 
survival compared to the free drug. This study reports for the first time dual nuclear imaging and drug 
delivery (Gem) of HA conjugates to solid tumors in mice. The conjugates show great potential in 
targeting, imaging and killing of CD44-over expressing cells in vivo. This work is likely to open new 
avenues for the application of HA-based macromolecules in the field of image-guided delivery in 
oncology.  
Key words: Gemcitabine, Hyaluronic acid, Image-Guided Delivery, SPECT, Nuclear Imaging, CD44-receptor, 
Endocytosis. 
Introduction 
Polymer-based nanocarriers, specially 
polymer-drug conjugates, have attracted much 
attention in cancer therapy [1] due to flexibility in 
macromolecular synthetic methods, diversity of 
polymers in terms of source, composition and ease of 








weight drugs to polymers alters the drug’s organ 
biodistribution profile, provides target specific 
delivery and reduces systemic toxicity. There are 
several polymer-anticancer drug conjugates that have 
reached clinical development [4-10] 
paclitaxel-polyglutamic acid conjugate (XYOTAXTM), 
for example, showed promising results in phase III 
clinical trials in women with non-small-cell lung 
cancer [11]. Despite these successes one key issue that 
is often neglected in the clinical application of 
macromolecular delivery is quantifying how much of 
the injected polymer reaches the tumor site. This is 
further complicated by the heterogeneity in Enhanced 
Permeation and Retention (EPR) and targeting 
receptors expression among the different tumors.  
Positron Emission Tomography (PET) and single 
photon emission computed tomography/computed 
tomography (SPECT) are two of the main imaging 
methods used in clinical practice [12, 13]. 
Radionuclides used in PET imaging have very short 
half-lives, so finding an instant nuclear labelling 
method of high radiolabelling efficacy, i.e., no 
purification is needed, is always sought. 
Tris(hydroxypyridinone) (THP) has been reported to 
offer instant and stable chelation with gallium 
radiometals, offering an attractive labelling approach 
in Positron Emission Tomography (PET) (68Ga) and 
SPECT (67Ga) imaging of peptides [14, 15]. 
Gemcitabine (Gem) is a bifluorinated 
deoxycytidine analogue prodrug, which internalizes 
into cells via the human equilibrative nucleoside 
transporter-1 (hENT1), a sodium-independent 
pathway. Following its entry into cells, Gem is 
phosphorylated into its mono-, di- and tri-phosphate 
derivatives, dFdCMP, dFdCDP and dFdCTP, 
respectively, by the action of deoxycytidine kinase 
(dCK). The active metabolite dFdCTP incorporates 
into the DNA of cancer cells, as a false nucleoside 
moiety, leading to cell proliferation inhibition and cell 
apoptosis [16-18]. It demonstrates a broad range of 
anticancer activity in hematological malignancies and 
against several solid tumor types [19, 20].  
Gemcitabine·HCl is marketed clinically, in more 
than 70 countries, as a parenteral formulation 
(Gemzar®), injected via intravenous (i.v.) infusion at a 
dose of 1000-1250 mg/m2 over 30 min, on a weekly 
basis, for 3-4 weeks [21]. Its clinical beneﬁt, however, 
is limited by its short plasma half-life (about 15 min) 
[22]; it undergoes rapid deactivation by the action of 
deoxycytidine deaminase, present in the blood and 
liver [23], followed by renal excretion. Such 
pharmacokinetic (PK) and pharmacodynamic (PD) 
profiles suggest that more frequent dosing is required. 
In some cases, daily administrations or prolonged 
infusions are required so that a therapeutic effect of 
the drug can be obtained [24, 25]. Higher doses of 
Gem are associated with serious side effects such as 
myelosuppression, thrombocytopenia, mild and 
transient neutropenia and anemia [26]. In addition to 
the PK/PD complexity, nucleoside transporters are 
needed for intracellular internalization of Gem and so 
drug resistance develops over time, diminishing Gem 
therapeutic efficacy [20, 27]. 
Polymer-Gem conjugates have been proposed, as 
one of the solutions, to improve Gem’s plasma 
stability, therapeutic efficacy and therapeutic index. 
Gem conjugation to polyethylene glycol (PEG) [28] 
and linoleic acid [29], via its N4-position, prolonged 
blood circulation time and improved its 
bioavailability as compared to the free drug. Other 
types of polymer conjugate such as an amphiphilic 
polymer like poly(ethyleneglycol)-block-poly(2- 
methyl-2-carboxyl-propylene carbonate) [30] and the 
polyisoprenoy prodrug of Gem [31] have been 
proposed, reporting improvements in plasma stability 
and in vivo antitumor efficacy after i.v. injection, in a 
MIAPaCa-2 cell derived xenograft model. In another 
approach, Gem has been conjugated to fatty acids 
(C3–C16) and subsequently incorporated into 
liposomes [32, 33]. This approach improved plasma 
stability, enhanced in vitro cytotoxicity and in vivo 
antitumor efficacy of all conjugates, and particularly 
stearoyl-Gem, compared to unmodified Gem [34]. 
HA is a natural polysaccharide, composed of an 
alternating unit of N-acetyl-D-glucosamine and 
D-glucuronic acid, and is present in the extracellular 
matrix and synovial ﬂuid [35]. It has been widely 
explored in anticancer drug delivery owing to its 
unique properties as a biodegradable, biocompatible, 
non-toxic, and non-immunogenic polymer. Targeting 
the CD44-receptor, over expressed in several types of 
cancer cells [36], attracted the attention of the 
scientific community, complemented by the 
experimental work showing improvements in the 
therapeutic efficacy of some anticancer drugs [37-39]. 
For example, paclitaxel-hyaluronan bioconjugate, 
targeting CD44 receptor, exhibited potent therapeutic 
activity against IGROV-1 and OVCAR-3 ovarian 
cancer xenografts model in vivo [40]. Multi-prodrug 
nanocarriers have been developed in which Gem and 
paclitaxel were coupled separately to HA and poly 
(L-lysine)-carboxylate, respectively. A synergistic 
anticancer activity was shown in HuCCT1 tumor 
bearing BALB/c nude mice following tail vein 
injection of both conjugates [41]. 
Considering the above drug shortcomings, we 
synthesized a Gem-HA conjugate, via an amide 
linkage as a more stable analogue in vivo. Conjugation 
of Gem to HA using the amide linkage has not been 
reported before. In general amide linkages are more 




stable than ester linkages so it is hypothesized that 
this strategy is likely to improve the plasma stability 
of Gem; prolong it's biological activity, and if 
successfully delivered to solid tumors, could delay 
tumor growth of CD44-expressing solid tumor 
models, following i.v. administration. The only study 
previously reporting Gem conjugation to HA utilized 
an ester linkage [41]. Moreover, it was reasoned that 
replacement of the Gem moiety with a fluorescent or 
nuclear imaging probe would allow in vitro 
(intracellular trafficking) or in vivo imaging 
(SPECT/CT), respectively. Conjugation of a THP 
chelator to HA has not been attempted previously, 
and if successfully achieved, could permit both PET 
and SPECT imaging. 
In this study, a tripodal HA conjugate; enabling 
the targeting, imaging and therapy of 
CD44-expressing cancer cells in vivo was synthesized. 
Chemical characterization, in vitro cell tracking and 
cytotoxicity studies were performed in a range of 
cancer cells. In vivo tumor biodistribution studies were 
carried out in two CD44-expressing tumor-bearing 
mice; the highly vascularized murine colon cancer 
(CT26) and the highly resistant human pancreatic 
cancer (PANC-1) mice models. Tumor accumulation 
was quantified by gamma scintigraphy. Finally, an in 
vivo therapeutic efficacy study was performed in the 
CT26 tumor model, at suboptimal Gem dose < 20-40 
mg/Kg [42].  
Materials and Methods 
Materials and Reagents 
Hyaluronic acid (MW 51 kDa) was purchased 
from Lifecore Biomedical (USA). The Gemcitabine 
free base was purchased from LC Laboratories (USA). 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC), N-hydroxysuccinimide (NHS), 
triethylamine (TEA), dipyridamole, anhydrous 
Dimethyl sulfoxide (DMSO), 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium-
bromide (MTT) were purchased from Sigma 
(UK).4'-(Aminomethyl) fluorescein, hydrochloride 
(4’-AMF) was purchased from Life Technologies 
Limited, UK. Tris(hydroxypyridinone) amine 
(THP-amine) was synthesized in our labs as 
previously reported [43]. Snake Skin dialysis tubing 
(MWCO 10 kDa) was purchased from Thermo-ﬁsher 
(USA). Anti-CD44 antibody (ab157107) was 
purchased from Abcam, UK. Dulbecco's Modified 
Eagle Medium (DMEM), Advanced RPMI-1640 
medium, fetal bovine serum (FBS), 
penicillin/streptomycin, trypsin/EDTA, and 
phosphate buffered saline (PBS) were obtained from 
Gibco (Thermo Fisher Scientific Inc, UK). The 
radioactive probe [67Ga] was purchased from 
Mallinckrodt Pharmaceuticals (Netherlands) as 
‘Gallium Ga67 Citrate solution for injection’ and the 
solution was used directly without further 
purification. Instant thin layer chromatography paper 
impregnated with silica gel (iTLC-SG) was obtained 
from Agilent Technologies (UK). BD ﬂow cytometry 
tubes were obtained from VWR (UK). Isoﬂurane 
(IsoFlo) for anesthesia was purchased from Abbott 
Laboratories Ltd (UK). Heparinised micro-capillaries 
(5 µL, Hirschmann Laborgerate) were purchased from 
VWR (UK). Acetonitrile (ACN) for HPLC was 
purchased from S D Fine-Chem Limited India. All 
reagents were used without further purification. 
Preparation of the Conjugates 
HA sodium salt (51 kDa, 1 g) was dissolved in 
deionized water (20 mL), and dialyzed against a 
dilute HCl solution (pH 3.5) and then deionized water 
using a dialysis tube (MWCO 10 kDa), for 12 h each, 
followed by lyophilization. To prepare the HA-Gem 
conjugate, the desalted HA (600 mg, 1.5 mmol of 
carboxyl group) was dissolved in 6 mL of anhydrous 
DMSO under nitrogen. Subsequently, EDC (575 mg, 3 
mmol) and NHS (345 mg, 3 mmol) dissolved in 
anhydrous DMSO (2 mL), were slowly added to the 
HA solution. The mixture was stirred for 1 h at room 
temperature to activate the HA carboxylic group. 
After 1 h, Gem (790 mg, 3 mmol) and TEA (418 μL, 3 
mmol) were added to the activated HA solution. 
Subsequently, the solution was allowed to react for 24 
h at room temperature. After the completion of the 
reaction, the reactant was puriﬁed by successive 
dialysis (MWCO 10 kDa) against an excess of 0.1 M 
NaCl, 25 % (v/v) ethanol solution and then deionized 
water. The solution was then lyophilized and stored 
at -20 °C until further use. A similar procedure was 
applied for the synthesis of HA-THP and HA-4’-AMF 
except that THP-amine and 4’-AMF were added in 
place of Gem. Details relating to these two reactions 
are provided in the supplementary information.  
Characterization of the Conjugates 
The synthesized conjugates were characterized 
by UV–visible spectrometry, nuclear magnetic 
resonance (1H NMR) and gel permeation 
chromatography (GPC). The Gem content in the 
HA-Gem conjugate was confirmed by UV (Perkin 
Elmer, Lambda 35, UV/VIS Spectrometer, USA) and 
the quantitative measurement was performed using a 
Gem calibration curve by measuring absorbance at 
268 nm. For the analysis, the samples were dissolved 
in PBS (pH 7.4) and scanned in the range from 350 to 
230 nm. The NMR spectra were recorded using 
deuterium oxide (D2O) as asolvent (Bruker 400 MHz, 




Bruker, Billerica, MA, USA). GPC analysis was 
performed using a Waters Chromatograph embedded 
with an ERC-7515A refractive index detector and 
Styragel® columns (7.8 mm x 300 mm x µμm). The 
detection range varied from 1 kDa to 10 MDa. The 
analysis was carried out using THF as an eluent at a 
flow rate of 1 mL/min. The THP-amine content in 
HA-THP conjugate was confirmed and quantified by 
UV–visible spectrometry. HA-4’-AMF was 
characterized by fluorescence spectroscopy as 
described in the supplementary information. 
Stability of HA-Gem in Mouse Plasma 
The stability of HA-Gem conjugate in mouse 
plasma was performed using a previously reported 
method with slight modiﬁcation [29]. Gem (0.8 mg) or 
HA-Gem conjugate (equivalent to 0.8 mg of Gem) was 
added to 1 mL of plasma and incubated at 37 °C for 48 
h. At scheduled time intervals, 100 μL of the plasma 
was taken out and replaced with the same amount of 
fresh plasma. Subsequently, 500 μL of ACN was 
added to 100 μL of each of the test plasma sample to 
precipitate the protein. The resulting mixture was 
vortexed for 5 min to extract the drug and centrifuged 
at 15000 rpm for 5 min at 4 °C. The supernatant was 
analyzed with RP-HPLC (SHIMADZU prominence, 
Japan), using a C-18 column (C-18G 250 x 4.5 mm), 
operated at 30°C with PDA detector (SPD-M20A) at a 
wavelength of 266 nm. The mobile phase consisted of 
ACN/water (70:30, v/v) with a flow rate of 1 
mL/min. Drug concentrations were calculated from a 
Gem calibration curve prepared under the same 
conditions (Figure S1). 
Hemolysis Assay 
The hemolysis assay was performed according to 
our previously optimized method [44]. Fresh red 
blood cells (RBCs) were collected by centrifugation 
(3000 rpm, 10 min) from healthy human blood. The 
supernatant was discarded and the settled RBCs were 
washed three times with PBS (pH 7.4). The pellet 
containing RBC was further diluted with the PBS 
(1:10). The diluted RBC suspension (0.1 mL) was 
added to Gem or Gem-HA (19 and 38 μM) solutions, 
or HA at an equivalent concentration, prepared in the 
PBS (0.9 mL). Distilled water and PBS were used as 
positive (100 % hemolysis) and negative (0 % 
hemolysis) controls, respectively. Samples were 
incubated at 37 °C for 2h in a shaker-incubator. The 
samples were then centrifuged (4000 rpm, 5 min) to 
settle down the non-lysed RBCs. The supernatant was 
analyzed by using a microplate reader at 576 nm and 
the percent hemolysis was estimated by the formula: 
% Hemolysis = 100(Abs−Abs0)/(Abs100-Abs0) 
Where, Abs, Abs100, and Abs0 are the absorbance of 
the samples, negative control (100 % hemolysis) and 
positive control (0% hemolysis), respectively. 
Cell Culture 
The human pancreatic carcinoma PANC-1 
(PANC-1; ATCC® CRL-1469TM) and PANC-0403 
(PANC-0403; ATCC® CRL-2555TM) cells, CT26 murine 
colon carcinoma (CT26; ATCC, CRL-2638), and 
B16-F10 murine melanoma (B16-F10; ATCC, 
CRL-6475) were cultured in Advanced RPMI (1640, 
1X) media. Human melanoma MDA-MB 435 cells 
(MDA-MB 435; ATCC® HTB-129) were cultured in 
DMEM. The media was supplemented with 10 % FBS, 
1 % L-glutamine, 50 U/mL penicillin, 50 µg/mL 
streptomycin. The cells were routinely grown in 75 
cm2 canted-neck tissue culture ﬂask in an incubator at 
37 °C in 5 % CO2 and passaged regularly by using 
Trypsin/EDTA when conﬂuence of 90 % was reached 
and sub-cultured. 
CD44 Expression Study 
To evaluate the CD44 expression on the cell 
surface, PANC-1, PANC-0403, CT26, B16-F10 and 
MDA-MB 435 cells were collected by trypsinization 
and transferred into BD ﬂow cytometer tubes. Cells (5 
x 105 cells of each cell line) were incubated with rat 
anti-CD44 monoclonal antibodies (#ab119863, Abcam, 
UK) for 30 min at RT, washed twice with PBS and 
stained with goat anti-rat antibodies conjugated with 
PE (#ab7010, Abcam, UK) for 30 min at RT. Cells were 
then washed and fixed with 4 % PFA. At least 10,000 
cells were gated and the fluorescence was measured 
using the 488 nm excitation line and the FL2 detector, 
BD FACS Calibur ﬂow cytometer (BD Bioscience, 
USA). The extent of CD44 expression was expressed 
as mean fluorescence intensity (MFI). 
In Vitro Cytotoxicity Studies  
The cancerous cell lines PANC-1, PANC-0403, 
CT26, B16-F10 and MDA-MB 435 were seeded in 
96-well plates and incubated with different 
concentrations of Gem or HA-Gem (200 μL of 0.01-100 
μM) in complete RPMI media for 24 and 72 h. The 
cytotoxicity was examined using a MTT assay. In 
brief, at the end of the incubation period, media was 
removed from the wells and replaced with 120 µL of 
MTT solution at a ﬁnal concentration of 0.5 mg/mL. 
After addition of MTT, cells were incubated for 3 h at 
37 °C under 5 % CO2. At the end of the incubation, the 
supernatant was removed from the wells and 
formazan was dissolved in 200 µL of DMSO. The plate 
was read at 570 nm in an FLUO star OPTIMA plate 
reader (BMG Labtech) and the results were expressed 
as the percentage cell viability (mean ± SD and 
calculated using the following equation: % Cell 
viability = (A570 nm of treated cells/A570 nm of 




untreated control cells) × 100. A similar procedure 
was applied to evaluate the cytotoxicity of different 
concentrations of native HA (200 μL of 0.1-1000 μM). 
Percentage viability was calculated as a percentage of 
untreated cells and expressed as mean ± SD (n = 5). 
The statics were applied using two-way ANOVA 
following a Bonferroni post comparison test. A p 
value of <0.05 was considered statistically signiﬁcant 
in all the studies. 
Nucleoside Transporter Inhibition Assay 
For the nucleoside transporter inhibition assay, 
CT26 and PANC-1 cells were seeded in 96- well 
plates. Dipyridamole was used as a nucleoside 
transporter inhibitor and the cells were pre-incubated 
with 10 μM dipyridamole for 30 min. Different 
concentrations of Gem or HA-Gem (0.01-100 μM) 
were added to the wells and the incubation was 
extended along with the inhibitor for 24 and 72 h, at 
37 °C and 5 % CO2. At the end of the incubation 
period, media was removed from the wells and 
replaced with 120 µL of MTT solution. The MTT assay 
(as described above) was used to measure cell 
viability. 
In Vitro Cellular Uptake  
For cellular uptake, CT26 cells were seeded in 
advanced RPMI media overnight in 12-well plates at a 
density of 1 x 105 cells/well. The cells were incubated 
with 20 or 40 µg/mL of HA-4’-AMF for 1 or 4 h, at 37 
°C and 5 % CO2. After incubation, cells were washed 
three times with PBS, trypsinized and washed with 
RPMI. The cells were centrifuged at 1500 rpm for 5 
min and the pellet was re-suspended in 300 µL of PBS. 
The HA-4’-AMF ﬂuorescence was measured using 
ﬂow cytometry in which 10,000 cells were gated and 
ﬂuorescence was measured in triplicate using the 488 
nm excitation line and the FL1 and FL2 detector, BD 
FACS Calibur ﬂow cytometer (BD Bioscience, USA).  
Endocytosis Inhibition 
To investigate the pathways by which 
HA-4´-AMF is taken up by cells, various uptake 
inhibitors were tested on PANC-1 and CT26 cells. 
Cells were seeded in 6-well plates at a density of 2 x 
105 cells/well overnight. The cells were pre-incubated 
with either sodium azide (10 mM) and deoxyglucose 
(5 mM), as an energy-dependent metabolic inhibitor, 
or cytochalasin D (2 μM), as a macropinocytosis 
inhibitor, for 15 min. After that, 40 µg/mL of 
HA-4´-AMF was added to the wells and co-incubated 
for 1 h, at 37 °C and 5 % CO2. Subsequently, the cells 
were washed three times with PBS, trypsinized and 
collected by centrifugation at 1500 rpm for 5 min. The 
pellets were re-suspended in 300 μL PBS into BD ﬂow 
cytometer tubes. The internalization of HA-4´-AMF 
was studied on 10,000 gated cells by measuring 
4´-AMF ﬂuorescence using a FL1 channel detector and 
a BD FACS Calibur ﬂow cytometer (BD Biosciences). 
The measurements were performed in triplicate and 
presented as means ± SD (n=3). 
CD44 Inhibition 
For CD44 inhibition, PANC-1 and CT26 cells 
were seeded in 12 well plates at a density of 1 x 105 
cells/well overnight. On the next day, the plates were 
kept on an ice bath for 10 min and 50 μg/mL of 
anti-CD44 (prepared in cold RPMI media) was added 
and left on ice 10 min. The plates were removed from 
the ice bath and 40 µg/mL of HA-4´-AMF was added 
to the wells and incubated for 1 h at 37 °C and 5 % 
CO2. After incubation, media was removed, washed 
three times with PBS, trypsinized and collected into 
BD ﬂow cytometer tubes. The internalization of 
HA-4´-AMF in the cells was measured by ﬂow 
cytometry as described previously. 
Cell Cycle Analysis by Flow Cytometry 
 To examine cell cycle alterations induced by 
Gem and HA-Gem, ﬂow cytometry analysis was 
performed. Brieﬂy, CT26 cells were seeded in 12 well 
plates at a density of 1 × 105 cells/well overnight. The 
cells were treated with Gem (2 μM), HA-Gem 
(equivalent to 2 μM of Gem) or HA (equivalent 
amount) for 24 and 48 h. After treatment, cells were 
washed two times with PBS, trypsinized and collected 
into BD ﬂow cytometer tubes. The cells were 
centrifuged 1500 rpm for 5 min, washed with PBS, 
re-suspended in 100 µL of PBS and 900 µL of 70% cold 
ethanol and placed at 4 °C for 1 h to fix and 
permeabilize the cells. Cells were then washed with 
PBS and treated with 50 µL of RNase (100 µg/mL in 
PBS). The DNA was stained with 400 µL of propidium 
iodide (PI) solution (40 µg/ml of PI in PBS) in the dark 
at 37 °C for 30 min. PI fluorescence was analyzed by 
flow cytometry using a BD FACS Calibur (BD 
Bioscience, US). Finally, 10,000 cells were gated and 
fluorescence was measured in triplicate for each 
condition by using the 488 nm excitation line and the 
FL2 detector and analyzed by FlowJo software. 
Results were expressed as averages of percentage cell 
populations in each phase of the cell cycle ± SD (n= 3). 
Radiolabelling of HA-THP and Labelling 
Stability Studies 
Radiolabelling of HA-THP with [67Ga] was 
performed by mixing equal volumes of HA-THP 
solution (1 mg/mL in H2O) and [67Ga] citrate salt 
solution (pH 7), at room temperature for 5 min. [67Ga] 
citrate alone, HA (1 mg/mL) and THP-amine (1 
mg/mL) solutions underwent the same labelling 
conditions and were used as controls. All solutions 




were spotted onto TLC strips, developed in 0.1 M 
citrate (pH 4.5) as the mobile phase and allowed to 
dry before analysis. The auto-radioactivity of the 
strips was developed and counted quantitatively 
using a Cyclone phosphor detector (Packard 
Biosciences, PerkinElmer Inc., UK). The 
[67Ga]HA-THP solution was buffered with NaCl to 
achieve final NaCl concentration as 0.9 % prior to 
injection for in vivo studies. The stability of 
radiolabelling was examined by incubating the 
[67Ga]HA-THP citrate saline solution alone or mixing 
with an equal volume of FBS at 37 °C for 24 h, 
followed by TLC analysis. 
Tumor Implantation for In Vivo Studies 
All in vivo experiments were conducted under 
the authority of project and personal license granted 
by the UK Home Office and the UKCCCR Guidelines 
(1998). Female Balb/c mice aged 4-6 weeks (Envigo, 
UK) were inoculated subcutaneously with CT26 cells 
(1 × 106 cells in 0.1 mL PBS) in the lower flanks. 
Female NSG mice aged 4-6 weeks (Charles River, UK) 
were inoculated subcutaneously with PANC-1 cells (5 
× 106 cells in 0.1 mL PBS) in the lower flanks. Nuclear 
imaging studies were conducted in mice carrying one 
tumor in one flank; biodistribution and therapy 
studies were performed in mice carrying two tumors 
one in each flank. Normal C57/Bl6 mice aged 4-6 
weeks (Envigo, UK) without tumor inoculation were 
used for the assessment of the biodistribution of 
THP-amine. 
Whole Body 3D SPECT/CT Imaging of 
[67Ga]HA-THP in CT26 Tumor-Bearing Mice 
Following Intravenous Injection 
In vivo uptake of [67Ga]HA-THP following i.v. 
injection was examined firstly by 3D whole body 
SPECT/CT imaging. Two weeks after tumor 
inoculation, CT26 tumor-bearing mice were 
anesthetized by isoflurane inhalation and i.v. injected 
with 200 μg of [67Ga]HA-THP (1 mg/mL in citrate 
saline, 10 MBq). SPECT/CT imaging was carried out 
immediately, and at 4 h and 24 h after injection, on the 
same animal in the prone position using the 
Nano-SPECT/CT scanner (Bioscan, USA). The SPECT 
scans were acquired over 24 projections (60 s per 
projection), using a 4-head scanner with 1.4 mm 
pinhole collimators, for a total acquisition time of 
30-40 min. CT scans were performed using a 45 kVP 
X-ray source after each SPECT imaging. SPECT 
images were reconstructed using HiSPECT (Scivis 
GmbH, Germany) and CT images were reconstructed 
using InVivoScopeTM, proprietary Bioscan software. 
Both images were fused and analyzed by 
InVivoScopeTM. SPECT/CT imaging was also carried 
out in CT26 tumor-bearing mice i.v. injected with 
[67Ga] or [67Ga]THP-amine (10 MBq in citrate saline) 
as controls to compare the biodistribution patterns.  
Blood, Excretion and Organ Biodistribution 
Profiles of [67Ga]HA-THP in Two 
Tumor-Bearing Mice Models 
Pharmacokinetic studies including blood 
circulation, excretion profiles and distribution in 
major organs of [67Ga]HA-THP were carried out in 
both CT26 tumor-bearing Balb/c mice and PANC-1 
tumor-bearing NSG mice. When tumors reached the 
desired size (~ 200 mm2, roughly at two weeks and 5 
weeks post-inoculation for CT26 tumors and PANC-1 
tumors, respectively), mice were injected with 
[67Ga]HA-THP (200 µg HA-THP, ~1 MBq) via a tail 
vein. Blood samples were collected in heparinized 
micro-capillaries from 2 min up to 24 h post-injection. 
To obtain the excretion profiles, mice were housed 
singly in metabolic cages in which animals had free 
access to water but not food. After 24 h, urine and 
feces were collected from individual cages. To assess 
the biodistribution profiles, organs of principle 
interest including skin, liver, spleen, heart, lung, 
muscle, bone, brain, stomach, intestine and tumor 
were excised and weighed post mortem at 1, 4 and 24 
h post-injection. The radioactivity of above tissues 
was counted by γ-scintigraphy (LKB Wallac 1282 
Compugamma, PerkinElmer, UK). Results were 
calculated as percentage injected dose per organ (% 
ID/organ) or per gram organ (% ID/g) and expressed 
as mean ± SD (n=3). Normal C57/Bl6 mice aged 4-6 
weeks without tumor inoculation were injected with 
[67Ga]THP-amine. The blood profile and organ 
biodistribution at 1 and 24 h were assessed. 
In Vivo Anticancer Activity 
The therapeutic efficacy of the HA-Gem 
conjugate was investigated using CT26 tumor-bearing 
Balb/c mice. Different concentrations of free Gem 
were tested in mice firstly to select the appropriate 
therapeutic dose for HA-Gem, at one week post 
tumor inoculation; mice were randomly divided into 
four groups: (i) untreated (control); (ii) 10 mg/kg 
Gem; (iii) 40 mg/kg Gem and (iv) 120 mg/kg Gem. 
Mice were anesthetized using isoﬂurane and injected 
every 4 days for a total of 4 doses. To determine the 
therapeutic action of Gem versus HA-Gem, at one 
week post tumor inoculation, mice were randomly 
divided into five groups (n = 10): (i) Untreated 
(control); (ii) 15 mg/kg Gem (free drug); (iii) 30 
mg/kg Gem; (iv) 15 mg/kg HA-Gem and (v) 30 
mg/kg HA-Gem. Mice were anesthetized using 
isoﬂurane and injected every 4 days via tail vein for a 
total of four doses. The tumor size and animal weight 




was measured three times each week. Animals were 
sacriﬁced when tumors reached 1000 mm3. Tumor 
sizes are presented as mean values ± SEM (standard 
error of the mean). Significant differences were 
examined using one-way ANOVA following a 
Bonferroni post comparison test for tumor growth 
delay studies. A p value of <0.05 was considered 
statistically signiﬁcant in all the studies. Log-rank 
(Mantel-Cox) test was performed for survival analysis 
using Graph Pad Software.  
Histological Examination of Major Organs 
At the experimental end points of therapy 
studies, animals were sacriﬁced and major organs 
including heart, lung, liver, spleen and kidney were 
excised. The organs were rinsed with PBS and then 
immediately ﬁxed in 10 % neutral buffered formalin 
as 5 mm2 pieces. Tissue sections were processed for 
Haematoxylin & Eosin (H&E) staining according to 
standard histological protocols at the Royal 
Veterinary College, UK. Stained sections were 
analyzed using a Leica DM 1000 LED Microscope 
(Leica Microsystems, UK) coupled with CCD digital 
camera (Qimaging, UK). 
Statistical Analysis 
The data were presented as mean ± S.D. for all 
experiments, except for therapy studies where 
standard error of the mean (S.E.M.) was used. n 
denotes the number of repeats. Statistical differences 
were examined using one-way ANOVA in which p < 
0.05 was considered as signiﬁcantly different in all 
studies. Statistical analysis for therapy, tumor growth 
and survival studies is described in the same section. 
Results 
Rationale of the Tripodal Design and Synthesis 
In this study, we designed tripodal HA 
conjugates suitable for in vitro and in vivo therapy and 
imaging. The carboxylate group of HA was activated 
using EDC/NHS chemistry, prior to conjugation to 
the amino group of Gem (therapy), 4’-AMF (in vitro 
tracking) or THP-amine (for 67Ga chelation and in vivo 
imaging). The summary of the design is described in 
Scheme 1. Conjugates were puriﬁed by dialysis and 
the solid product obtained upon lyophilisation was 
stored at -20 °C until further use. The yield of 
HA-Gem, HA-4’-AMF and HA-THP conjugate was ~ 
94 %, 91 %, and 90 %, respectively. 
Confirmation of Gem Conjugation by 1H NMR 
and GPC 
1H NMR spectroscopy was used to confirm Gem 
conjugation to HA (Figure 1). HA and HA-Gem 
present a peak at 1.88 ppm (-CH3-g of the acetamido 
moiety of N-acetyl-D-glucosamine). The characteristic 
Gem peaks are shown at 7.86 (-CH-b), 6.10 (-CH-a), 
4.23 (-CH-d) and 3.94 (-CH-e). These peaks were also 
present in the dialyzed HA-Gem, confirming 
successful conjugation. The formation of HA-Gem 
conjugate was further conﬁrmed by GPC analysis. 
The retention volumes of HA and HA-Gem were 
19.49 mL and 15.28 mL, respectively (Figure 2). The 
reduction in HA retention volume upon conjugation 
was in line with previous studies [45, 46], supporting 
the NMR results, and confirming the successful 
conjugation of Gem to HA. 
 
Scheme 1. Scheme for synthesis of HA conjugates. The chemical synthesis scheme describing conjugation strategy of hyaluronic acid (HA) to Gemcitabine (Gem), 
4'-(aminomethyl) fluorescein hydrochloride (4’-AMF), or tris(hydroxypyridinone) amine (THP-amine) using EDC/NHS chemistry. 









Figure 2. GPC analysis. GPC spectra of hyaluronic acid (HA) and HA conjugated 
Gemcitabine (HA-Gem). The analysis was performed with GPC equipped with 
ERC-7515A refractive index detector using a Styragel® column and THP as a mobile 
phase at elution rate of 1 mL/min. Retention times for HA and HA-Gem are 19.49 and 
15.28 ml, respectively.  
 
Quantification of Gem, 4’-AMF or THP in the 
Conjugates 
UV spectroscopy was used to quantify Gem, 
4’-AMF or THP loading onto HA. Gem and 
THP-amine exhibit UV absorbance at 268 nm and 288 
nm, respectively (Figure 3A, C). No peak shift was 
observed upon conjugation to HA. The fluorescence 
spectrum of 4’-AMF showed an emission maximum at 
515 nm when excited at 480 nm (Figure 3E). Standard 
curves of Gem, 4’-AMF or THP (Figure 3B, D and F) 
were used to calculate the degree of substitution in 
HA-Gem, HA-4’-AMF or HA-THP which was 
calculated as ~38.15 µg/mg, 11.12 µg/mg or 10.45 
µg/mg, respectively. 
HA-Gem Exhibits Improved Stability and 
Sustained Drug Release in Mouse Plasma 
It is widely reported that native Gem is 
converted into its inactive metabolite 2′, 
2′-diﬂuorodeoxyuridine by cytidine deaminase [23], 
when administered via i.v. route. Contrary to Gem, 
which underwent enzymatic degradation following 
37 °C incubation in plasma (23 % remaining at 4 h), 
HA-Gem showed sustained Gem release, with 7 % 
and 21 % drug being steadily released at 4 and 48 h of 
incubation time points (Figure 4A).  
HA-Gem Shows Lower Hemolytic Activity 
than Gem 
Dose limiting hematopoietic toxicity was 
reported for Gem [47]. Gem conjugation to HA 
showed a significantly lower hemolytic activity at 
both concentrations tested (19 and 38 μM). Percentage 
hemolysis of 12 % and 33 %, 2 % and 6 % were 
reported for free Gem, HA-Gem at 19 and 38 μM, 




respectively (Figure 4B). As expected, no hemolytic 
activity was found for HA. The results suggest good 
in vitro hemocompatibility of HA-Gem, as previously 
suggested by others [48]. 
HA-Gem Is Active In Vitro in a Range of 
CD44-Expressing Cancer Cell Lines 
The cellular cytotoxicity of Gem and HA-Gem 
was evaluated by MTT assay in cancer cell lines 
expressing CD44 receptors to different degrees; 
PANC-1>CT26>PANC-0403> B16-F10 = MDA-MB 
435 (Figure S2). Cells were incubated with Gem in the 
form of free drug or the conjugate, at 0.01-100 μM for 
24 and 72 h. Dose- and time-dependent reductions in 
cell viability were observed in all cell lines (Figure 5). 
In all cell lines except CT26, no significant difference 
in cell viability between Gem and HA-Gem was 
observed at 24 h. Free Gem, however, showed slightly 
significantly higher cytotoxicity than HA-Gem at 72 h 
in most of the cell lines, presumably due to differences 
in internalization mechanisms and release kinetics 
compared to the free drug. CT26 showed the highest 
sensitivity amongst all the cell lines tested. No toxicity 
was observed for HA (without the drug) under 
conditions tested for Gem in PANC-1 and 




Figure 3. Absorption spectra and standard curves of the synthesized conjugates. (A) UV absorption spectra of HA, Gem and HA-Gem. (B) Standard curve of Gem 
in distilled water at 268 nm. (C) UV absorption spectra of HA conjugated tris(hydroxypyridinone) amine (HA-THP), HA and THP-amine. (D) Standard curve of THP-amine in 
PBS (pH 7.4) at 288 nm. (E) Fluorescence emission spectrum of HA conjugated 4'-(aminomethyl) fluorescein hydrochloride (HA-4’-AMF), at 480 nm excitation wavelength. (F) 
Standard curve of HA-4’-AMF (or 4’-AMF) in PBS (pH 10), at 480 nm and 515 nm excitation and emission wavelengths, respectively. 





Figure 4. Ex vivo characterisation of the HA-Gem; in plasma for stability 
and in blood for hemolysis. (A) Time dependent estimation of Gem in plasma 
following release from HA-Gem. The free Gem or the conjugate was incubated with 
mouse plasma for 48 h at 37 °C. At scheduled time intervals, samples were taken and 
Gem quantified by RP-HPLC at a wavelength of 266 nm, mobile phase consisted of 
acetonitrile/water (70:30, v/v) and flow rate of 1 mL/min. (B) Ex vivo hemolytic activity 
studies on RBCs. The RBCs were incubated with Gem, HA-Gem, HA for 2 h at 37 °C. 
Distilled water and PBS (pH 7.4) were used as positive (100 % hemolysis) and negative 
controls (0% hemolysis), respectively. Data are reported as mean of three 





Nucleoside Transporter Inhibition Reverses 
the Anticancer Activity of Gem, but not 
HA-Gem 
The activity of Gem is dependent on nucleoside 
transporters, which are required for internalization 
into cells. Reduced nucleoside transporter activity 
resulted in resistance to Gem therapy [49]. We have 
tested the effect of nucleoside transporter inhibition 
on the internalization of Gem, using 10 μM 
dipyridamole, which is a non-specific inhibitor of 
hENT1 transporters [50]. This resulted in significantly 
lower cytotoxicity for Gem but not the conjugate, in 
both cell lines tested; CT26 and PANC-1 (Figures 6 
and S4). This further confirmed that the free drug but 
not the conjugate is internalized into the cells using 
nucleoside transporters.  
 
Figure 5. In vitro cytotoxicity assay. Concentration 
dependent anticancer effect of Gemcitabine (Gem) and 
hyaluronic acid conjugated Gemcitabine (HA-Gem) was 
confirmed in a range of cancer cell lines (Pancreatic: 
PANC-1, PANC-0403; colon: CT26; melanoma: B16-F10; 
and breast: MDA-MB 435) using the MTT assay, at 24 h and 
72 h post-incubation. Percentage viability was calculated as 
a percentage of untreated cells and expressed as mean ± 
SD (n = 5). * P < 0.05, ** P < 0.01, *** P < 0.001 
 
  





Figure 6. Nucleoside transporter inhibition assay. The effect of nucleoside transporter inhibition, using dipyridamol, on Gem and HA-Gem cytotoxicity was studied using 
a MTT assay, in CT26 and PANC-1 cells. Cells were pre-incubated with dipyridamol (10 µM) for 30 min, prior co-incubation with different concentration (0.01 to 100 μM) of 
Gem or HA-Gem for 72 h. Percentage viability was assessed by the MTT assay and calculated as a percentage of untreated cells and expressed as mean ± SD (n = 5). * P < 0.05, 
** P < 0.01, *** P < 0.001 Gem versus HA-Gem. 
 
 
In Vitro Uptake of HA-4’-AMF in Colon CT26 
and Pancreatic PANC-1 Cells is 
Macropinocytosis- and CD44-dependent  
HA enters into cells via CD44 receptor-mediated 
endocytosis [36, 37, 39]. We tested the uptake of 
fluorescently labelled HA, HA-4’-AMF, in two CD44 
expressing cell lines which exhibited the highest CD44 
expression amongst the cell lines tested 
(PANC-1>CT26). The uptake of HA-4’-AMF in CT26 
was dose- and time-dependent (Figure 7A). A general 
endocytosis inhibition condition, sodium azide (10 
mM) and deoxyglucose (5 mM), resulted in inhibition 
of HA-4’-AMF uptake in both cell lines (Figure 7B). 
Similarly, Cytochalasin D (2 μM), a macropinocytosis 
inhibitor, resulted in uptake inhibition, more 
extensively in CT26 cells (Figure 7C). To determine if 
the uptake is CD44-receptor dependent, receptors 
were blocked with anti-CD44 (50 μg/mL) prior 
HA-4’-AMF treatment. This resulted in uptake 
inhibition, more especially in PANC-1 cells (Figure 8), 
in contrast to the Cytochalasin D effect. These studies 
concluded that both macropinocytosis and CD44 
receptors are involved in HA uptake. CT26 appears to 
be more dependent on macropinocytosis than the 
CD44 receptor, for HA internalization, and vice versa 
for PANC-1.  
HA-Gem and Gem Shift the Cell cycle of CT26 
from G1 to S phase 
Cell cycle analysis was investigated at 24 and 48 
h post-treatment (2 µM Gem concentration) using 
flow cytometry. Gem-treated cells showed ≈ 72 % of 
cells arrested in S phase after 24 h (Figure 9 A, B) 
while no apparent changes could be seen for Gem-HA 
or HA treatments, agreeing with the reduction of in 
vitro toxicity observed for Gem-HA with MTT the 
assay. However, cells treated for 48 h with Gem and 
HA-Gem showed a steady increase of ≈ 80 % of cells 
arrested in G1 phase (Figure 9 A, B). HA did not show 
any effect on the cell cycle analysis.  
[67GA]-Radiolabelling of HA-THP Conjugate 
and Stability Studies 
In this study, a rapid and efficient labelling 
reaction with the γ-emitter [67Ga] at neutral pH and 
room temperature was observed. As shown in the 
iTLC images (Figure 10A), free [67Ga] and [67Ga] HA 
alone appeared at the solvent front. Most of the 
radioactivity of [67Ga]THP-amine and [67Ga]HA-THP 
was observed at the application point. Some smeared 
through the ILC strips but did not travel to the solvent 
front, indicating the binding of [67Ga] with 
THP-amine, and the successful radiolabelling of 
HA-THP with [67Ga]. The labelling stability was 
examined by incubating equal volumes of 
[67Ga]HA-THP with saline or serum at 37 °C for 30 
min, 4 h, and 24 h. iTLC results showed that the 
[67Ga]HA-THP remained stable without the 
observation of radioactivity spots at the solvent front 
(Figure 10B). 
In Vivo Whole Body SPECT/CT Imaging  
Whole body SPECT/CT images of uncomplexed 
[67Ga], [67Ga]THP-amine and [67Ga]HA-THP in CT26 
tumor-bearing mice at multiple time points up to 24 h 
post-injection are shown in Figure 11. The three 
compounds showed marked differences in their in 
vivo biodistribution over the time course. 
[67Ga]THP-amine was rapidly cleared through 
urinary excretion since radioactivity was detected 
exclusively in kidney and bladder within 30 min after 




injection. This is in contrast to the distribution of 
[67Ga] where most of the activity was present in the 
circulation after injection, located throughout the 
whole mouse at 4 h, accumulated in the bone at 24 h. 
In the case of [67Ga]HA-THP, it displayed a relatively 
high concentration in the circulation but also 
exhibited renal excretion at early times post injection. 
The accumulation of [67Ga]HA-THP in liver, spleen 
and tumor was observed, and the uptake in CT26 
tumor increased over time. No tumor uptake was 
detected for [67Ga] and [67Ga]THP-amine. 
In Vivo Tumor Uptake and Organ 
Biodistribution Studies of [67Ga]HA-THP in 
CT26 and PANC-1 Tumor-Bearing Mice 
The organ biodistribution and tumor uptake 
profiles of [67Ga]HA-THP following i.v. injection were 
assessed quantitatively by γ-scintigraphy in two 
tumor models. As shown in Figure 12A-B, similar 
blood and excretion profiles were obtained in both 
tumor-bearing mice models. [67Ga]HA-THP showed 
long blood circulation time, in line with the 
SPECT/CT imaging results. More than 30 % of the 
injected dose (% ID) was detected in urine over 24 h in 
both models, whereas the amount detected in feces 
was invariably small. The uptake in major organs 
correlated well with SPECT/CT imaging results in 
which most [67Ga]HA-THP were detected in liver and 
spleen and the accumulation in these organs increased 
over time (Figure 12C-D, the left panel). The high 
radioactivity detected in the heart and lung at early 
time points (i.e. 1 and 4 h) was related to high blood 
concentrations. Uptake in kidney was monitored, 
suggesting urinary excretion of [67Ga]HA-THP. The 
tumor accumulation profiles of [67Ga]HA-THP 
between the two models were clearly different (Figure 
 
Figure 7. Effect of endocytosis inhibitors on cellular uptake of HA-4´-AMF in vitro. (A) CT26 cells were incubated with the fluorescently labelled HA (HA-4´-AMF) 
for 1 or 4 h at 20 µg/mL or 40 µg/mL at 37 °C. Flow cytometry histograms confirmed that the intracellular uptake of HA-4’-AMF in CT26 cancer cells is time- and 
concentration-dependent. (B) The influence of general energy inhibition (sodium azide, 10 mM and deoxyglucose, 5 mM)) (red line). (C) Macropinocytosis (cytochalasin-D, 2 
μM) (green line) on HA-4´-AMF uptake (black line). All treatments resulted in uptake inhibition. Cells were pre-incubated with either inhibitor for 15 min prior co-incubation 
with both the inhibitor and HA-4´-AMF (40 µg/mL for 1 h). 




12C-D, the right panel). Increasing uptake in CT26 
tumors over time was observed in which the 
accumulation at 4 h and 24 h were significantly higher 
than 1 h post injection (p < 0.05 and p < 0.01, 
respectively) and the values were measured above 1 
% ID/g of tumor. The uptake of [67Ga]HA-THP in 
PANC-1 tumor was lower, compared to CT26 tumors 
and the amounts (% ID/g of tumor) detected at 
different time points were not significantly different 
(< 1 % ID/g of tumor).  
Blood and organ biodistribution profiles of 
[67Ga]THP-amine were also assessed in normal 
C57/Bl6 mice (Figure S5A-B). The results from 
quantitative γ-scintigraphy analyses correlated with 
the SPECT/CT imaging although using different mice 
strains. Fast clearance from the blood circulation and 
body was observed within the first-hour post 
injection. The organ biodistribution profiles of 
[67Ga]HA-THP in both models expressed as % 
ID/organ are expressed in Figure S5C and S5D 
respectively. The organ biodistribution at 1, 4 and 24 h 
post injection of HA in CT26 and PANC-1 bearing 
mice (µg (HA)/g tissue) is tabulated in Table S1. 
Reduced HA-Gem Dose Delays Tumor 
Growth and Improves Survival of CT26 
Tumor-Bearing Balb/c Mice 
The anticancer potential of HA-Gem was 
investigated in CT26 tumor-bearing Balb/c mice. 
Firstly, the effective dose of Gem was determined in 
CT26 tumor-bearing mice following i.v. 
administration. Mice injected with 40 (21 ± 4 mm3) 
and 120 mg/kg (15 ± 3 mm3) of Gem exhibited 
significantly smaller tumor volume by day 20 (p < 
0.05), when compared to 10 mg/kg Gem (291 ± 70 
mm3) and untreated mice (453 ± 96 mm3) (Figure 
S6A). There were no significant differences in tumor 
volumes between untreated and 10 mg/kg Gem was 
observed. Changes in body weights remained within 
the 10 % weight loss range allowed in this type of 
treatment (Figure S6B). Suboptimal doses of 15 and 
30 mg/kg of Gem were therefore selected for 
comparing the in vivo efficacy of Gem and its HA 
conjugate. 
On day 28 post-therapy with Gem or HA-Gem, 
tumor volumes of mice treated with 15 mg/kg Gem 
or HA-Gem were 316 ± 83 or 61 ± 21 mm3 (p < 0.05), 
respectively, while 30 mg/kg treated resulted in 161 ± 
68 and 25 ± 4 mm3 volumes for the respective 
treatments (p > 0.05) (Figure 13A). These results 
demonstrated that multiple injections of HA-Gem 
resulted in a significantly delayed tumor growth 
compared to the free drug at doses as low as 15 
mg/kg). No significant changes in the body weights 




Figure 8. Effect of CD44 inhibition on cellular uptake of HA-4´-AMF in vitro. CT26 or PANC-1 cells were co-incubated with the fluorescently labelled HA 
(HA-4´-AMF) (40 µg/mL, black line) and anti-CD44 (50 μg/mL, blue line) for 1 h at 37 °C, to inhibit uptake via CD44 receptor. The cells were pre-treated with anti-CD44 for 10 
min at 4 °C. (A) Flow cytometry histograms and (B) % inhibition indicate significant inhibition of the uptake in both cell lines. 





Figure 9. Cell cycle distribution analysis at 24 and 48 h in CT26 cells in vitro. The cells were seeded in 12 well plates at a density of 105 cells/well and then treated with 
(2 μM Gem concentration) free Gem or HA-Gem or HA for 24 and 48 h. (A) Representative histograms showing the cell cycle distribution and (B) Relative changes in the 
percentage of the cell cycle phases following 24 and 48 h indicate a shift in cell cycle distribution from G1 to S phase, which is more apparent at 24 h of Gem post-treatment. Cell 
cycle arrest in G1 phase was induced after 48 h post-treatment of both Gem and HA-Gem. Values are expressed as mean ± SD (n = 3). 
 
Log-rank survival analysis was carried out 
(Figure 13B). Interestingly, animals received HA-Gem 
showed significantly longer survival time compared 
to untreated mice or mice treated with free Gem. 
No Histological Abnormalities are Found Post 
Therapy in Major Organs of CT26 
Tumor-Bearing Mice 
For histological examination, major organs 
including heart, lung, liver, spleen and kidney were 
excised at the experimental end points of therapy 
studies. The tissue sections were preceded for H&E 
staining. Despite the promising anti-tumor effect of 
HA-Gem, no obvious histological changes were 
observed in these major organs compared to 
untreated animals (Figure S8). The tissue sections 
from animals treated with free Gem showed no 
obvious histological abnormality either.  
Discussion 
Gem is one of the most effective anticancer drugs 
used for treatment several solid tumors [51]. 
However, rapid deamination leading to a short 
half-life necessitates its frequent administration in 
high doses to achieve chemotherapeutic efficacy [22, 
23]. Moreover, Gem requires nucleoside transporters 
to aid its transport across cell membranes. This can be 
an issue in nucleoside transporter-deﬁcient patients 
and can be associated with a high incidence of drug 
resistance. Preparation of macromolecular conjugates 




has been reported as one of the methods to tackle this 
problem [52].  
Our study differs from previously reported 
studies on HA-based macromolecular delivery in a 
few aspects. In this study, we report a versatile HA 
conjugate amenable to modification to accommodate 
Gem (drug) or a nuclear imaging chelator. A HA-THP 
conjugate is synthesized for the first time. The THP 
chelator facilitates chelation of SPECT (67Ga) or PET 
(68Ga) imaging probes. The binding constant for 
[67Ga]-THP is high ensuring no leakage of [67Ga] from 
the complex. The high affinity also ensures a rapid 
and almost complete radiolabelling reaction. 
[67Ga]THP has been used to radiolabelling proteins 
[14]. Application of this radiolabelling strategy to a 
polymer such as HA is an important step towards 
designing HA-based conjugates for image-guided 
delivery.  
HA pre-clinical imaging was reported 
previously with PET [53, 54] and CT/SPECT [55, 56] 
or MRI [57, 58] techniques. One study reported the 
distribution of [99mTc]-labelled HA into connective 
tissues after oral administration in rat [55]. In another 
study, tyramine-modified HA was radiolabelled with 
[125I] and its organ distribution examined following 
oral administration. Most of the conjugate remained 
localized in the stomach and intestine [56]. Two 
studies on PET imaging of HA-based nanocarriers, 
using either NOTA or DOTA chelators, were reported 
[53, 54]. In one PET imaging study, 
1,4,7-triazacyclononane -1,4,7-triacetic acid 
(NOTA)-HA conjugate was synthesized and 
radiolabelled with 68Ga. PET imaging was carried out 
to detect myocardial infarction in rats. Higher 
accumulations of radiolabelled conjugate into the 
infarct than in healthy cardiac tissue was observed. 
This is due to the hyaluronan-receptor-induced 
targeting in the infarct area [53]. The closest to our 
study was PET imaging of HA-single-walled carbon 
nanotube hybrid, labelled 64Cu (HA-64Cu-DOTA-NTs) 
[54], which showed high tumor uptake in the CD44 
positive, SCC7 tumor-bearing mouse model. This 
however is different from our study in that it is 
imaging the NTs functionalized with HA as opposed 
to HA as a macromolecular carrier. The organ 
biodistribution of HA polymer and 
HA-functionalized NTs is very different. The use of 
HA conjugated to THP, as a chelator, is totally novel. 
The combination of HA-Gem conjugate and HA-Gem 
conjugate offers qualitative tumor uptake data and 
potent treatment of CD44-expressing tumors in the 
same study. 
 
Figure 10. Radiolabelling of HA-THP-amine with [67Ga] and mouse serum stability studies. iTLC examination of (A) radiolabelling efficiency and (B) 
radiolabelling stability. Equal volume of HA-THP solution (1 mg/mL in H2O) and [67Ga] citrate solutions were mixed at room temperature for 5 min. [67Ga], HA (1 mg/mL), 
THP-amine (1 mg/mL) solutions were tested as controls. Labelling efficiency was analysed by iTLC using 0.1 M citrate (pH 4.5) as the mobile phase. For stability studies, 
[67Ga]HA-THP solution was diluted with saline to final NaCl concentration at 0.9 % (w/w). An aliquot of solution was mixed with an equal volume of FBS (50 % serum). Both 
solutions were kept at 37 °C and examined by iTLC after 30 min, 4 h and 24 h of incubation.  





Figure 11. Whole body 3D SPECT/CT imaging of [67Ga], [67Ga]THP-amine and [67Ga]HA-THP in CT26 tumor-bearing Balb/c mice. Mice were i.v. injected 
with 10 MBq of [67Ga], [67Ga]THP-amine (200 µg) or [67Ga]HA-THP (200 µg). SPECT/CT imaging was carried out immediately after injection and at 4 h and 24 h post injection. 
The whole body image is presented in the left panel and the transverse images of selected organs are presented in the right panel. Abbreviations: Heart (H), lung (L), liver (Li), 
spleen (Sp), kidney (Ki), tumor (Tu) and bladder (Bl). In the [67Ga] treated group, tumor (Tu) and bladder (Bl) are captured in the same image, the bottom transverse images. Since 
the signals in spleen of [67Ga]THP-amine group were not detectable and spleen is not CT contrast organ, transverse images of spleen for these mice are not available. 
 
To our knowledge, this is the ﬁrst report which 
describes the preparation of HA-Gem conjugate that 
can be used for dual imaging and (mono) therapy of 
CD44-overexpressing tumors in vivo. It is expected 
that a mixture of HA-Gem and a trace of HA-THP can 
be administered to patients if image-guided delivery 
of this conjugate is to be implemented in clinical 
practice. Regulatory approval is likely to be more 
straightforward for 2 known chemical entities mixed 
in the same vial rather than the one conjugate 
containing both THP and Gem. The latter approach is 
likely to have more variability from one batch to 
another. Both Gem and THP were conjugated to HA 
via a relatively stable amide linkage, which is more 
stable than the ester linkage reported in the previous 
study [41]. Gem release from HA is expected to occur 
intra-cellularly, following CD44 mediated 
intra-cellular internalization. The molecular weight 




(MW) of HA chosen in this study (~51 kDa) has been 
reported to favor interactions with hyaluronan/CD44 
receptor. Lower MW HA(< 30 kDa) exhibits lower 
affinity to the receptor [59] while higher MWHA 
forms a gel or precipitates from water [60]. The 
novelty of the performed study lies in many aspects 
including the method of synthesis, quantifying the 
targeting efficiency of HA in both highly vascularized 
murine colon cancer (CT26) and the highly resistant 
human pancreatic cancer (PANC-1) mice models and 
validating the use of HA-Gem conjugate as single 
agent for cancer therapy in vivo. 
As expected, our study showed that Gem 
conjugation to HA protects it from degradation in 
plasma. This is possibly due to the involvement of the 
primary amine group in the amide bond formation, 
making it unavailable for the action of degradative 
enzymes. Following incubation of HA-Gem in 
plasma, a100 µL sample was withdrawn at 0, 15 min, 
0.5, 1, 2 4, 6, 8, 12, 24 and 48 h, to which 500 µL of ACN 
was added to precipitate the protein and aid the 
extraction of the drug. An equal volume of fresh 
plasma was used to replace the release medium 
withdrawn. The results shown in Figure 4(A) 
demonstrated that the drug was slowly released from 
the conjugates in the presence of plasma. The slow 
Gem release from the conjugate, is beneficial as it is 
intended that Gem is not released prematurely in 
blood/plasma. After reaching to the target site, the 
drug can dissociate from the polymer due to the acidic 
 
Figure 12. Blood, excretion and organ biodistribution profiles of [67Ga]HA-THP in CT26 tumor-bearing Balb/c mice and PANC-1 tumor-bearing NSG 
mice. (A) Blood concentrations and (B) excretion into urine and faeces, up to 24 h post injection. Major organ biodistribution at 1, 4 and 24 h post injection in (C) CT26 
tumor-bearing mice and (D) PANC-1 tumor-bearing mice. Tumor uptake is shown to the right. Mice were i.v. injected with 1 MBq of [67Ga] HA-THP (200 µg). For excretion 
profiles, mice were housed individually in metabolic cages for 24 h immediately after injection. Results are expressed as % ID/organ or % ID/g of organ measured by 
γ-scintigraphy. Data is presented as mean ± S.D. (n=3). *p < 0.05; **p < 0.01. 
 




microenvironment of the tumor [30]. Following 
internalization of HA-Gem into cells, the amide bond 
between polymer and drug can be enzymatically 
cleaved by the action of cathapsin B, a lysosomal 
protease. There are several reports on polymeric 
conjugates and prodrugs of gem that demonstrated 
the role of cathapsin B in cleavage of amide bond and 
release of drug inside the cells [30, 33, 61]. The 
conjugation results in reduced frequency of 
administration and reduced systemic side effects, i.e., 
hemolysis, and that a greater portion of HA-Gem is 
guaranteed to reach the tumor and target CD44 
receptor. Thus, in principle, less frequent drug 
administration will be required. The slow release 
kinetics in serum was further supported by the lower 
cytotoxicity of HA-Gem than Gem observed in in vitro 
studies performed in the presence of mouse serum. It 
is expected that receptor-mediated uptake (HA-Gem) 
is a slower process than for free Gem (passive 
diffusion). Studies by other groups have shown 
reduced in vitro Gem cytotoxicity when conjugated to 
different polymers such as poly(ethyleneglycol)- 
block-poly (2-methyl-2-carboxyl-propylene 
carbonate) [30] and poly-L-glutamic acid [62]. 
 
The nucleoside transporter inhibition study 
further confirmed that Gem and HA-Gem utilized 
two different internalization routes. This is in 
agreement with previous studies on 
Gem-phospholipid conjugates [63]. Interestingly our 
flow cytometry studies confirmed that HA 
internalization, as HA-4’-AMF, is energy dependent 
in both the cell lines tested: CT26 cells (colon) and 
PANC-1 cells (pancreatic). Cells, however, may favor 
one internalization route over another. 
Macropinocytosis was shown to play a more 
important role in HA internalization in CT26 than in 
PANC-1 cells. Cytochalasin D is a speciﬁc 
macropinocytosis inhibitor which stops the formation 
of actin ﬁlaments and membrane ruffling [64]. A 
previous study shared the similar findings in which 
HA endocytosed via macropinocytosis on B16-F10 
melanoma cells [65]. Our study showed that blocking 
the receptor with an anti-CD44 antibody, reduced HA 
uptake in both cell lines, but more evidently in 
PANC-1 cells. Our results altogether confirmed HA 
internalization via CD44-mediated endocytosis, 




Figure 13. Evaluation of in vivo anti-tumor effect of Gem and HA-Gem in CT26 tumor bearing BALB/c mice. (A) In vivo anti tumor effect of Gemcitabine (Gem) 
and hyaluronic acid conjugated Gemcitabine (HA-Gem) in the CT26 tumor bearing BALB/c mice. (B) Percentage survival of mice. The mice were transplanted subcutaneously 
with 1 × 106 CT26 cells. The animals were then divided randomly into five groups: Untreated (control), 15 mg/kg Gem (free drug), 30 mg/kg Gem, 15 mg/kg HA-Gem and 30 
mg/kg HA-Gem. Mice were intravenously administered a total of 4 injections on day 7, 10, 14 and 18 post-tumor inoculation (dotted vertical line) with the particular treatment. 
The size of the tumor was measured three times each week. Data are given as mean value ± SD (n = 8). One-way ANOVA was performed for tumor growth analysis following 
Bonferroni post comparison test. Log-rank (Mantel-Cox) test was performed for survival analysis using Graph Pad. *p < 0.05, **p < 0.01, ***p < 0.001. 
 




The HA-THP conjugate was radiolabelled with 
γ-emitter [67Ga] in order to track its organ and tumor 
biodistribution, in the respective in vivo tumor 
models. THP-amine has been reported as an efficient 
bifunctional [68Ga] chelator for PET imaging [14, 43]. 
67Ga has been in clinical use since 1980s for diagnostic 
imaging particularly for lymphoma. It has high 
affinity to blood and bone within hours after i.v. 
injection [69]. No free 67Ga was detected following 
incubation of [67Ga]THP-amine with human serum, at 
37 °C for 4 h, followed by size exclusion 
chromatography [43]. The present study further 
demonstrated the outstanding binding affinity of 67Ga 
to both THP-amine and also HA-THP; as shown by 
the distinctly different SPECT imaging profiles of67Ga, 
[67Ga]THP-amine or [67Ga]HA-THP. 
Gamma scintigraphy studies confirmed 
[67Ga]HA-THP targeting to CT26 and PANC-1 tumor 
following i.v. injection in mice (CT26>PANC-1). It is 
worth noting that there was a significant increase in 
tumor uptake over time, from 1 h to 24 h, in case the of 
CT26 tumors but PANC-1 showed steady values over 
time. This is not surprising as the murine CT26 tumor 
is a commonly used leaky and high vascular tumor 
model [70]. The human PANC-1 model on the other 
hand is poorly vascularized [71, 72]. The fact that 
PANC-1 cells express CD44 receptors at higher levels 
than CT26 suggests that tumor uptake in pancreatic 
cells can still occur, despite the compromised EPR 
effect in this tumor. Such difference in EPR may 
explain the increasing and steady tumor uptake 
pattern, over time, in CT26 and PANC-1 tumors, 
respectively. This indirect evidence of 
CD44-dependent uptake in PANC-1 cells in vivo 
complements the in vitro CD44-receptor inhibition 
data where PANC-1appeared to be more sensitive to 
uptake inhibition than CT26 cells.  
Drug conjugation to HA is expected to improve 
its plasma profile and slow its clearance. Paclitaxel 
loaded HA-octadecyl micelles exhibited longer 
elimination half-life in the circulation, and higher 
AUC than Taxol® solution, in rats [73]. In another 
report, HA-quercetin conjugate showed a 20.1-fold 
and 4.9-fold increase in the half-life and AUC of 
quercetin, respectively, after i.v. administration in rat 
[74]. It has previously demonstrated that Gem 
modification on the N-4 position protected the drug 
from deactivation by degradative enzymes in plasma 
[29, 30], prolonged its circulation half-life [28, 29] and 
improved its therapeutic index [29-31]. To our 
knowledge, only one study reported the formulation 
of HA-Gem. In this study, Gem was conjugated to HA 
via an ester linkage. Two drug-polymer conjugates 
were co-administered: Gem-HA and paclitaxel- poly 
(L-lysine)-carboxylate [41]. A synergistic in vivo 
anticancer activity, in HuCCT1 biliary cancer, was 
obtained at a total of 6 i.v. injections, at twice weekly 
intervals and a dose of 108.80 µg (Gem) and 54 µg 
(paclitaxel) per mouse. In our study, the dose given 
was ~375 µg per mice which is higher than the dose 
reported in this published study [41]. It is however 
worth noting that a therapeutic response was 
achieved following a total of 4 injections, as a single 
agent, in our study, as opposed to 6 dose and 
co-administration of polymeric paclitaxel [41].  
In our study, we have tested the cytotoxicity of 
free HA in CT26 and PANC-1cells in vitro, which was 
found to be non-cytotoxic up to 1000 µM. A number of 
in vivo reports suggested that HA has no effect on 
tumor growth rate. These studies were tested in SCC7 
tumor bearing BALB/c nude mice [75], H22 bearing 
Kunming mice [74] and H22 bearing ICR mice [76].  
To the best of our knowledge, this is the first 
time a HA-Gem conjugate has been reported as a 
single agent therapy. In our study, a 4-injection over a 
28-day treatment period demonstrated that the 
HA-Gem delivered to CT26 tumors in vivo were 
sufficient to delay tumor growth and to prolong mice 
survival, at doses of 15 mg/kg (p< 0.05) and 30 mg/kg 
(p> 0.05) (Gem), compared to the free drug. A 
previous study, employed a liposomal Gem 
formulation in a CT26 tumor model, used a dose of 
30-120 mg/kg for a total of 5 injections, repeated 
every third day [77]. No changes in body weight or 
histological abnormalities were seen confirming the 
biocompatibility of the conjugate. This result suggests 
that lowering the Gem dose, in the form of HA 
conjugate, can improve Gem therapeutic efficacy in 
vivo. This is likely to improve the therapeutic index of 
the drug as a whole and provide an effective 
treatment at a lower dose.  
Conclusion 
This work describes for the first time the 
synthesis of a tripodal HA conjugate, capable of 
SPECT imaging and cancer therapy in vivo. This is the 
first study reporting SPECT imaging of HA, as a 
macromolecular drug conjugate, in cancer 
applications. Furthermore, the use of THP, a Ga 
chelator, adds to the attractiveness of the approach as 
both SPECT (long-lived isotopes for pharmacokinetic 
studies) and PET (short-lived isotopes for clinical 
imaging studies) imaging can be performed. The 
fluorescently labelled conjugate provided information 
on the possible cell entry mechanisms employed in 
both CT26 and PANC-1 cells in vitro. Gamma 
scintigraphy and in vivo live imaging studies 
described the quantities of HA that reached the 
tumor, allowing for a correlation between tumor 
concentrations and therapeutic efficacy to be made. It 




was concluded that the HA-Gem conjugate was safe 
to use and resulted in improved therapeutic efficacy 
against CD44-expressing tumors, compared to the 
free drug, at significantly lower doses that what has 
been previously reported.  
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